Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampyra Trial Failure Is Not All Bad News For Acorda

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.

You may also be interested in...



Ampyra Seizure Warnings Strengthened Followed Continued Reports

The seizure risk for Acorda’s multiple sclerosis drug was already known, but an FDA MedWatch Alert based on post-market adverse event reports says, “the majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.”

The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan

Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.

Everything Old Is New Again: History Of Compounding Shaped Ampyra REMS

Acorda’s Ampyra (dalfampridine) is a first-in-class new molecular entity in terms of FDA approval, but the drug substance’s history as a compounded drug raised the concerns necessitating a Risk Evaluation and Mitigation Strategy, FDA’s review documents show.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel